HOME                 |                      AGENDA                 |                     SPEAKERS                    |                   REGISTER                 |               CONTACT US
|   INTELLECTUAL PROPERTY & SCIENCE
(215) 823 - 5305
(215) 901 - 9811
QUESTIONS?

For all event inquiries, please contact Jessica Corrado

For all PR related inquiries, please contact Jennifer Figueroa
ACCELERATE AND ENHANCE YOUR R&D

The broadest and deepest resource of pharmaceutical intelligence solutions and professional services on the market.

Thomson Reuters provides the knowledge, tools and expertise to support your drug discovery and development activities, optimize your IP portfolio, identify licensing and partnering opportunities, deliver successful regulatory submissions, keep you in touch with the rapidly changing pharmaceutical and chemical markets, and make the best decisions for your business.

Visit lifesciences.thomsonreuters.com for more information.

ABOUT THOMSON REUTERS

Thomson Reuters is the leading source of intelligent information for professionals around the world. Our customers are knowledge workers in key sectors of the global economy. We supply them with the intelligent information they need to succeed in fields that are vital to developed and emerging economies such as law, financial services, tax and accounting, science and media.

Our knowledge and information is essential for drug companies to discover new  drugs and get them to market faster, for researchers to find relevant papers and know what’s newly published in their subject, and for businesses to optimize their intellectual property and find competitive intelligence.

For more information visit lifesciences.thomsonreuters.com
BIOWORLD TODAY: THE DAILY BIOPHARMACEUTICAL NEWS SERVICE FROM THOMSON REUTERS

BioWorld delivers actionable intelligence on the most innovative drug development science that drives the business, which funds the means to heal disease. With writers and editors stationed around the globe, BioWorld Today reports the breaking news — and provides key perspective — on hundreds of medicines in development, the companies behind those therapeutic candidates, the business development transactions that evolve the market, and the regulatory hurdles that both challenge and guard the process.

Visit www.bioworld.com for more information